ArticleWorld journal of clinical cases2025
Revitalizing liver health: Human placental extract shows promise in chronic liver disease management.
Article in World journal of clinical cases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This editorial provided commentaries on an article titled "Liver function improvement after human placental extract injections in patients with chronic liver disease: Thirty case reports". The first clinical application of an innovative therapeutic protocol was comprehensively described in this case report by Lee, in which 30 patients with chronic liver disease (CLD) received intravenous administration of 10 mL human placental extract (HPE). Notably, significant improvements in liver function could be observed in these patients, which underscored the potential of this novel treatment for CLD management. However, the rising prevalence of CLD around the world underscored the limitations of conventional therapies (such as antiviral agents and lifestyle modifications) in addressing advanced fibrosis or metabolic dysfunction-associated steatotic liver disease. Additionally, emerging regenerative therapies (including HPE) have garnered more attention due to their bioactive components, which could modulate the hepatic microenvironment based on antioxidant, anti-inflammatory, and pro-regenerative mechanisms. Although the existing evidence remains relatively lacking, the multi-targeted action of HPE highlights its potential as a novel therapeutic strategy. Overall, this editorial outlines the research advancements of HPE, alongside the critical analysis of existing limitations and the proposal of future research directions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.